Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category

References

• Rheingold J J, Kaufman R, Adelson E, Lear A. Smouldering acute leukemia. N Engl J Med 1963; 28: 812–816
   Web of Science ®Google Scholar
• Koeffler H P, Golde D W. Human preleukemia. Ann Int Med 1980; 93: 347–353
   PubMed Web of Science ®Google Scholar
• Greenberg P L. The smouldering myeloid leukemic states: clinical and biologic features. Blood 1983; 61: 1035–1044
   PubMed Web of Science ®Google Scholar
• Aul C, Bowen D T, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83: 71–86
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87: 746–754
   PubMed Web of Science ®Google Scholar
• Brunning R D, Bennett J M, Flandrin G, Matutes E, Head D, Vardiman J W, . Myelodysplastic syndromes. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman, et al. IARC Press, Lyon 2001; Vol. 1: 62–73
   Google Scholar
• Lyons J, Janssen J W, Bartram C, Layton M, Mufti G J. Mutations of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988; 71: 1707–1712
   PubMed Web of Science ®Google Scholar
• Bartram C R. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6: 557–570
   PubMed Web of Science ®Google Scholar
• Stephenson J, Mufti G J, Yoshida Y. Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. Int J Hematol 1993; 57: 99–112
   PubMed Web of Science ®Google Scholar
• Greenberg P L. Apoptosis and its role in myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998; 22: 1123–1136
   PubMed Web of Science ®Google Scholar
• Parker J E, Mufti G J. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001; 73: 416–428
   PubMed Web of Science ®Google Scholar
• Deeg H J, Beckham C, Loken M R, Bryant E, Lesnikova M, Shulman H M, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000; 37: 405–414
   PubMed Web of Science ®Google Scholar
• Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy P L, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002; 75: 289–297
   PubMed Web of Science ®Google Scholar
• Gidali J, Feher I, Hollan S R. Blast colony forming cell-binding capacity of bone marrow stroma from myelodysplastic syndrome. Stem Cells 1996; 14: 577–583
   PubMed Web of Science ®Google Scholar
• Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999; 23: 239–246
   PubMed Web of Science ®Google Scholar
• Tauro S, Hepburn M D, Bowen D T, Pippard M J. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001; 86: 1038–1045
   PubMed Web of Science ®Google Scholar
• Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci P F, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999; 81: 1398–1401
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplatic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, et al. Significance of angiogenin plasma concentrations in patients with acute myeloid leukemia and advanced myelodysplastic syndrome. Br J Haematol 2001; 114: 290–295
   PubMed Web of Science ®Google Scholar
• Bellamy W T, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434
   PubMed Web of Science ®Google Scholar
• Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Haematother Stem Cell Res 2002; 11: 119–125
   PubMedGoogle Scholar
• Aguayo A, Kantarjian H M, Estey E H, Giles F J, Verstovsek S, Manshouri T, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923–1930
   PubMed Web of Science ®Google Scholar
• Wimazal F, Jordan J H, Sperr W R, Chott A, Dabbass S, Lechner K, et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol 2002; 160: 1639–1645
   PubMed Web of Science ®Google Scholar
• Ghannadan M, Wimazal F, Simonitsch I, Sperr W R, Mayerhofer M, Sillaber C, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol 2003; 119: 663–671
   PubMed Web of Science ®Google Scholar
• Krauth M T, Simonitsch I, Aichberger K J, Mayerhofer M, Sperr W R, Sillaber C, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am J Clin Pathol 2004; 121: 473–481
   PubMed Web of Science ®Google Scholar
• Tuzuner N, Bennett J M. Reference standards for bone marrow cellularity. Leuk Res 1994; 18: 645–647
   PubMed Web of Science ®Google Scholar
• Perez-Atayde A R, Sallan S E, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815–821
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Valent P, Sperr W R, Griffin J D, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767–3775
   PubMed Web of Science ®Google Scholar
• Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998; 273: 18165–18172
   PubMed Web of Science ®Google Scholar
• Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim J A, Turner A R, Ratajczak M Z. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002; 16: 1160–1166
   PubMed Web of Science ®Google Scholar
• Sillaber C, Mayerhofer M, Aichberger K J, Krauth M T, Valent P. Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest 2004; 34(Suppl 2)2–11
   PubMed Web of Science ®Google Scholar